Fiscal Note

SB0086 - Amendments to Preferred Drug List

State Impact:
Enactment of this bill will result in savings in FY 2010 of $240,000 General Fund and $600,300 Federal Funds ($840,300 total). Additionally there are ongoing savings in FY 2011 of $362,500 General Fund and $906,800 Federal Funds ($1,269,300 total).

Funding SourceFY 2009
Approp.		FY 2010
Approp.		FY 2011
Approp.		FY 2009
Revenue		FY 2010
Revenue		FY 2011
Revenue
General Fund$0($362,500)($362,500)$0$0$0
General Fund, One-Time$0$122,500$0$0$0$0
Federal Funds$0($600,300)($906,800)$0$0$0
   Total
$0
($840,300)
($1,269,300)
$0
$0
$0

Individual, Business and/or Local Impact:
Enactment of this bill likely will not result in direct, measurable costs and/or benefits for individuals or local governments. The savings listed above come through payments for generic drugs rather than brand name drugs. Those businesses providing the generic drugs would see increased revenues while businesses providing brand name drugs would see a decrease in revenues.

1/29/2009, 10:53:18 AM, Lead Analyst: Frandsen, R.Office of the Legislative Fiscal Analyst